Celecoxib Therapy For RRP Dr. Bettie Steinberg, Dr. Allan Abramson, Dr. Mark Shikowitz LIJ Medical Center Dr. Richard Smith, Dr. Harry Hoffman - Univ.

Slides:



Advertisements
Similar presentations
Herceptin as a Phase 0 Imaging Example. Phase 0 Trials in Oncology Drug Development Steven M. Larson, M.D. Nuclear Medicine Svc, Department of Radiology.
Advertisements

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.
Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.
Vitamin D3 for Health, Cancer Prevention and Recovery Georgia Tetlow, MD.
ACRIN 6673 MULTICENTER FEASIBILITY STUDY OF PERCUTANEOUS RADIOFREQUENCY ABLATION OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS Final Report from Central.
Neel Bhalala (2009) Sofia Medical University. Background  Erythropoiesis-stimulating agents are man-made versions of a natural protein known as erythropoietin.
Oncology The study of cancer. What is cancer? Any malignant growth or tumor caused by abnormal and uncontrolled cell division May be a tumor but it doesn’t.
Synthesis, functions and
Nonsteroidal Anti- inflammatory Drugs ผศ. พญ. มาลียา มโนรถ.
The Cell Cycle and Cancer. Cell signaling: chemical communication between cells. Click on above to go to animation second chemical response inside the.
Bio 130 Human Biology Cancer Normal cells have regulation that keeps their rates of cell division in check. Normal cells generally remain in one location.
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in chondrosarcomas Makoto Endo, 1 Tadaki Matsumura, 2 Umio Yamaguchi, 1 Fumihiko.
Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.
What are lifestyle diseases?
Advances in Lung Transplantation: A Patient Guide David J. Lederer, M.D., M.S. Assistant Professor of Medicine New York Presbyterian Lung Transplant Program.
Hematology/Oncology Fellowship Kristie A. Blum, M.D. Gregory Otterson, M.D. The Ohio State University Department of Medicine, Division of Hematology &
Principal Investigator
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
MEDICINAL CHEMISTRY- III introduction Wed. 2/ 5/ 1432H Prof. Dr. Wafaa Zaghary PHC 426.
Non-steroidal Anti- Inflammatory Drugs And Their Effect on Renal Function.
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Linda Snetselaar, PhD, RD Professor Interim Chair of the Department of Community and Behavioral Health College of Public Health University of Iowa.
Cancer What is cancer? How does it form? How can it be treated?
Copyright © 2006 Pearson Education, Inc. publishing as Benjamin Cummings.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Recurrent Respiratory Papillomatosis (RRP): Basic Science to Clinical Studies Mark J. Shikowitz, MD Bettie M. Steinberg, PhD Long Island Jewish Medical.
Bettie M. Steinberg, PhD Chief Scientific Officer The Feinstein Institute for Medical Research Dean, Elmezzi Graduate School of Molecular Medicine Professor.
EICOSANOIDS (prostaglandins, thromboxanes, leukotrienes)
Chapter 10: Non-narcotic Anti-Inflammatory Analgesics Presented by: Katie and Steffani.
SHIP protein identified as a B-cell tumor suppressor Lymphoma is a cancer of the immune system. White blood cells divide again and again, spreading abnormally.
Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,
Consent for Research Study A study for patients diagnosed with locally advanced breast cancer Learning if the imaging agent, [ 18 F] fluorothymidine (FLT),
Jenny T. Mao, M.D., FCCP Associate Professor Division of Pulmonary and Critical Care David Geffen School of Medicine at UCLA UCLA Lung Cancer Chemoprevention.
Celebrex ® (celecoxib): Another treatment for inflammation! Alberto Ponce Organic Chemistry 12B Spring 2006
CANCER. Background Cells divide and multiply as the body needs them. Cells divide and multiply as the body needs them. When cells continue multiplying.
Kidney Disorders. Kidney Transplant Many consider this to be the best method of treating kidney disease. A transplant may offer the best chance.
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
Phase 2 study of the mTOR inhibitor RAD001 (everolimus) in combination with bevacizumab (avastin) in patients with sporadic and neurofibromatosis type.
Simon K. Cheng 1, Kevin Stephenson 2, Lynn Shi 2, Kunal Chaudhary 1, Anshu Jain 1, David P. Horowitz 1, Sherry X. Yan 2, Tony Wang 1, Clifford Chao 1,
Tumor Markers American cancer society British Journal of Cancer By B.Heidari.
Cancer Basics EQ: What does cancer have to do with the cell cycle?
Copyright © 2008 Delmar Learning. All rights reserved. Unit 47 Caring for the Patient with Cancer.
Prostaglandin, Leukotriene, and Thromboxane Synthesis Eric Niederhoffer SIU-SOM Pathway overview Prostaglandin receptors Pathway details Differential actions.
Experiences (and frustrations) in Developing a Biotech Company in Idaho.
IN-1 Oncologic Drugs Advisory Committee Bethesda, Maryland January 31, 2002 C.
Regulating The Cell Cycle. Warm Up – The Cell Cycle The cell spends 80% of the time in _______________ and 20% of the time in ________________ What are.
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
NSAIDs in the Treatment and Prevention of Cancer
Peterson-Kaiser Health System Tracker What are recent trends in cancer spending and outcomes?
Cancer Objective What is Cancer? Cancer is uncontrolled cell growth. (Mitosis) When you are young, your cells grow fast so because you are growing.
What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
FRENCH high-resolution studies - Breast cancer: 1990, 1997, 2003, 2010 ? - Colorectal cancer: 1990, 1995, 2000, 2005, 2010 ? - Prostate cancer: 1995,
R2 민준기 / 정재헌 교수님. Introduction Patients with resected high-risk locally advanced head and neck cancer –Expect favorable outcomes after concomitant radiochemotherapy(CCRT)
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease : The St Francis Heart Study Randomized Clinical Trial Temitope Foster,
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin and Cancer J Am Coll Cardiol. 2016;68(9):
Omega Best Cancer Hospital - India
SURGICAL ONCOLOGY AND TUMOR MARKERS
Indiana State Cancer Registry
Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint
What is it? How is it treated? What makes a person susceptible to it?
“Traditional NSAIDs” versus “COXIBs”
Seeking Treatments for PSC Out of the Desert and into the Woods
Dr. Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
The heart and science of medicine.
Clinical responses in patients.
General Imaging Information
Presentation transcript:

Celecoxib Therapy For RRP Dr. Bettie Steinberg, Dr. Allan Abramson, Dr. Mark Shikowitz LIJ Medical Center Dr. Richard Smith, Dr. Harry Hoffman - Univ. Iowa Dr. Mark Courey – Univ. California, San Francisco Dr. Craig Derkay, Dr. John Sinacori – Eastern Virginia Medical School Dr. Glenn Peters, Dr. Paul Castellanos – Univ. Alabama, Birmingham Dr. Clark Rosen, Univ. Pittsburgh

Cyclooxygenase (COX-2) Enzyme elevated in inflammation Also elevated in many premalignant and malignant tumors – Colorectal polyps – Respiratory papillomas – Head and neck cancer – Breast cancer – Lung cancer – Cervical cancer – Prostate cancer Inhibiting COX-2 helps other types of tumors

COX-2 Activities Arachidonic Acid PGG 2 PGH 2 PGD 2 PGE 2 PGF 2a PGI 2 TXA 2 COX-2 angiogenesis, apoptosis, immune surveillance, differentiation

COX-2 and Its Product PGE 2 Are Expressed in Respiratory Papillomas COX-2 Neg control NormalPapilloma Relative COX-2 levels Normal Papilloma * * * Normal Papilloma PGE 2 (pg/ml) COX-2 NPNP PCon

Inhibiting COX-2 Reduces Papilloma Cell Proliferation and Increases Apoptosis * p < 0.05 ** p < 0.01

Months after randomization Growth Rate Months after randomization Growth Rate Months after randomization Growth Rate Three Patients Treated in Pilot Study All Free of Disease 12 months 18 months Trachea, Patient 3

New NIH Grant To Study Efficacy of Celebrex 5 year grant Enrolling patients beginning of year Grant will pay for patient travel to one of participating centers Celebrex provided by Pfizer at no cost Grant will permit us to determine whether Celebrex is an effective therapy for RRP, and if some patients respond and others do not, why

Eligibility Age 4 years or older 3 or more surgeries in past year or tracheal/ broncheal involvement No history of heart disease or current high blood pressure No significant kidney or liver disease Not allergic to Celebrex or sulfa drugs

Clinical Celecbrex Trial Study Design Celebrex Placebo Pre Treat Randomize 6 months 12 months Everyone gets Celebrex Study lasts 30 months for each patient Surgery every 3 months during the study, unless free of disease, then office evaluations every three months Blood tests every three months, at time of surgery, to help determine mechanism of response

If Interested in Participating Send patient records to: Dr. Allan Abramson or Dr. Mark Shikowitz Department of Otolaryngology Long Island Jewish Medical Center th Ave New Hyde Park, NY Tel: